









市場行情
/
股票
/
nasdaq-plrx
/

Pliant Therapeutics Inc

PLRX

1.230USD

+0.020+1.65%

收盤 12/19, 16:00（美東）報價延遲15分鐘

75.58M總市值

虧損本益比TTM



Pliant Therapeutics Inc

1.230

+0.020+1.65%

概覽公司財務分析

概覽

公司

財務

分析

關於 Pliant Therapeutics Inc 公司

Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Pliant Therapeutics Inc簡介



公司代碼PLRX

公司名稱Pliant Therapeutics Inc

上市日期Jun 03, 2020

CEOCoulie (Bernard J)

員工數量171

證券類型Ordinary Share

年結日Jun 03

公司地址331 Oyster Point Boulevard

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94080

電話16504816770

網址https://pliantrx.com/

公司代碼PLRX

上市日期Jun 03, 2020

CEOCoulie (Bernard J)

Pliant Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Bernard J. Coulie, M.D., Ph.D.

President, Chief Executive Officer, Director

705.63K

-8.97%

Dr. Hoyoung Huh, M.D., Ph.D.

Non-Executive Chairman of the Board, Lead Independent Director

99.76K

Dr. Suzanne Louise (Sue) Bruhn, Ph.D.

Independent Director

35.08K

Dr. John T. Curnutte, M.D., Ph.D.

Independent Director

29.28K

Ms. Lily Cheung

Chief Human Resources Officer

7.22K

-68.53%

Mr. Christopher Keenan

Vice President - Investor Relations and Corporate Communications

Dr. Eric Lefebvre, M.D.

Chief Medical Officer

Mr. David E. I. Pyott, CBE

Independent Director

Dr. Delphine Imbert, Ph.D.

Chief Technical Officer

Mr. Darren S. Cline

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Bernard J. Coulie, M.D., Ph.D.

President, Chief Executive Officer, Director

705.63K

-8.97%

Dr. Hoyoung Huh, M.D., Ph.D.

Non-Executive Chairman of the Board, Lead Independent Director

99.76K

Dr. Suzanne Louise (Sue) Bruhn, Ph.D.

Independent Director

35.08K

Dr. John T. Curnutte, M.D., Ph.D.

Independent Director

29.28K

Ms. Lily Cheung

Chief Human Resources Officer

7.22K

-68.53%

Mr. Christopher Keenan

Vice President - Investor Relations and Corporate Communications

收入明細

FY2024

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

0.00

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Tang Capital Management, LLC

9.77%

Woodline Partners LP

7.33%

Point72 Asset Management, L.P.

7.06%

Morgan Stanley & Co. LLC

5.69%

Blue Owl Capital Holdings LP

4.83%

其他

65.32%

持股股東

佔比

Tang Capital Management, LLC

9.77%

Woodline Partners LP

7.33%

Point72 Asset Management, L.P.

7.06%

Morgan Stanley & Co. LLC

5.69%

Blue Owl Capital Holdings LP

4.83%

其他

65.32%

股東類型

持股股東

佔比

Hedge Fund

37.34%

Investment Advisor

20.88%

Investment Advisor/Hedge Fund

12.64%

Research Firm

12.08%

Individual Investor

2.52%

Family Office

0.87%

Venture Capital

0.76%

Private Equity

0.04%

Bank and Trust

0.02%

其他

12.86%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

356

52.49M

85.42%

-37.39M

2025Q2

374

62.63M

102.02%

-15.09M

2025Q1

390

63.45M

103.37%

-12.99M

2024Q4

392

71.13M

116.20%

-8.66M

2024Q3

388

69.61M

114.50%

-7.63M

2024Q2

375

69.93M

115.87%

-7.66M

2024Q1

371

73.36M

121.74%

-3.24M

2023Q4

362

70.03M

116.83%

-95.89K

2023Q3

356

64.13M

107.25%

-2.06M

2023Q2

347

62.06M

104.99%

-496.00K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Tang Capital Management, LLC

6.00M

9.77%

Jun 30, 2025

Woodline Partners LP

2.35M

3.83%

-165.56K

-6.59%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.99M

3.25%

+965.53K

+93.93%

Jun 30, 2025

Blue Owl Capital Holdings LP

2.97M

4.84%

Jun 30, 2025

The Vanguard Group, Inc.

3.00M

4.89%

-322.88K

-9.71%

Jun 30, 2025

Acadian Asset Management LLC

1.63M

2.66%

+409.97K

+33.59%

Jun 30, 2025

Citadel Advisors LLC

2.36M

3.84%

+2.36M

+3624360.00%

Jun 30, 2025

J.P. Morgan Securities LLC

1.95M

3.18%

+1.52M

+352.69%

Jun 30, 2025

Two Sigma Investments, LP

745.40K

1.21%

+127.91K

+20.72%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

ProShares Ultra Nasdaq Biotechnology

0.01%

iShares Biotechnology ETF

0.01%

Invesco Nasdaq Biotechnology ETF

0.01%

DFA Dimensional US Core Equity Market ETF

Schwab U.S. Small-Cap ETF

Global X Russell 2000 Covered Call ETF

Humankind US Stock ETF

iShares Morningstar Small-Cap Value ETF

iShares Micro-Cap ETF

佔比0.02%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.01%

ProShares Ultra Nasdaq Biotechnology

佔比0.01%

iShares Biotechnology ETF

佔比0.01%

Invesco Nasdaq Biotechnology ETF

佔比0.01%

DFA Dimensional US Core Equity Market ETF

佔比0%

Schwab U.S. Small-Cap ETF

佔比0%

Global X Russell 2000 Covered Call ETF

佔比0%

Humankind US Stock ETF

佔比0%

iShares Morningstar Small-Cap Value ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Pliant Therapeutics Inc的前五大股東是誰？



Pliant Therapeutics Inc的前五大股東如下：
Tang Capital Management, LLC
持有股份：6.00M
佔總股份比例：9.77%。
Woodline Partners LP
持有股份：2.35M
佔總股份比例：3.83%。
Morgan Stanley & Co. LLC
持有股份：1.99M
佔總股份比例：3.25%。
Blue Owl Capital Holdings LP
持有股份：2.97M
佔總股份比例：4.84%。
The Vanguard Group, Inc.
持有股份：3.00M
佔總股份比例：4.89%。